Please enable JavaScript.
Coggle requires JavaScript to display documents.
Immunotherapy - Coggle Diagram
Immunotherapy
Checkpoint inhibitors
Markers
Present on Tumour cells
PD-L1
Ensure Physicians check for PD-L1 marker presence on patient's tumour cells.
biopsy of tumor required.
Present on T cells
PD-1
Inhibition of PD-1 on T cells activates them to hunt & destroy RCC cells.
Pembrolizumab
3-6 weeks interval
Administer for 2 years
30 minutes administration of IV drip
CTLA-4
nivolumab + ipilimumab
receptors inhibited
Targeted Therapy
Tyrosine Kinase Inhibitors
Reference
Initial probing
Cancer Research Checkpoint Inhibitors
Cancer Research Pembrolizumab
ipilimumab + nivolumab